LivaNova

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, LivaNova sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials 1 currently recruiting 8 completed later-stage tilt top decile by trial count

LivaNova: 13 sponsored US clinical trials, 1 recruiting.

LivaNova sponsors 13 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 8 completed. 5 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Patients Implanted With a Pacemaker, with 1 trials.

Top-decile sponsor footprint

LivaNova ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 21/100

8 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

13 total, page 1 of 1

RECRUITING NA

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

NCT03887715

ACTIVE NOT RECRUITING NA

Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Neurostimulation

NCT04950894

TERMINATED

The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes

NCT04753385

TERMINATED NA

ANTHEM-HFrEF Pivotal Study

NCT03425422

COMPLETED NA

Microburst Vagus Nerve Stimulator (VNS) Therapy Feasibility Study

NCT03446664

COMPLETED

Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

NCT03529045

TERMINATED NA

Mitroflow DL Post Approval Study- North America

NCT02351726

COMPLETED Phase 3

Clinical Evaluation of the Physiological Diagnosis Function in the PARADYM CRT Device

NCT02167789

COMPLETED Phase 4

Predictive Risk Stratification Through T Variability in ICD Patients Without Pacing Indications

NCT00560768

COMPLETED Phase 4

Evaluation of the SafeR Mode in Patients With a Dual Chamber Pacemaker Indication

NCT00562107

COMPLETED

Natural Evolution of AV Conduction Disorders in Patients Implanted With Cardiac Pacemakers

NCT00531037

COMPLETED Phase 4

Optimal Anti-tachycardia Therapy in Implantable Cardioverter-defibrillator (ICD) Patients Without Pacing Indications

NCT00729703

COMPLETED Phase 4

Prevention of Atrial Arrhythmia in Patients Without Atrioventricular (AV) Conduction Disease

NCT01170611

Where LivaNova enrollment is open (later-stage tilt)

1 recruiting of 13 indexed (8% open); 8 completed (62%).

Phase mix: 5 late (III/IV) vs 0 early (I/II) (later-stage heavy).

Top condition: Patients Implanted With a Pacemaker (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

LivaNova: open-pipeline peers nationwide

Peers matched on 13 registered trials and 8% open enrollment, not the therapeutic-area sidebar.

LivaNova sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 12.912.91313.1 0%2%4%6%8%10% Total trials Recruiting share LivaNovaAdaptimmuneAgennixAkili Interactive LabsAlumisAndrei IagaruBioXcel TherapeuticsCorporal Michael J. Crescenz VA Medical CenterFresenius Medical Care North America
LivaNova sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

LivaNova sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 trials (± recruiting share)

Sponsors near 8% open enrollment (± trial volume)

What to do with this LivaNova page

13 registered trials is a research-attention snapshot, not an endorsement of LivaNova or any single study.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

LivaNova pipeline card: 13 registered trials from official public datasets.Report a data error.